Duloxetine Hydrochloride Capsule, Delayed Release
Product Images NDC 46708-280

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine Hydrochloride (NDC 46708-280). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure diagram of duloxetine hydrochloride, the active ingredient in DULOXETINE HYDROCHLORIDE delayed-release capsules by Alembic Pharmaceuticals Limited. The structure includes a naphthalene moiety, a thiophene ring, and an amine group with hydrochloride.*

FDA Label Image

Duloxetine-fig1.jpg (Duloxetine Fig1)

A line graph depicting the proportion of patients with relapse over time in days from randomization, comparing two treatments: Placebo and Duloxetine. The x-axis represents time from randomization to relapse (in days), and the y-axis shows the proportion of patients with relapse. The graph includes two curves, one for placebo and one for duloxetine, illustrating their relapse rates over approximately 200 days.*

FDA Label Image

Duloxetine-fig2.jpg (Duloxetine Fig2)

A line graph showing the proportion of patients with relapse over time (days) from randomization. The graph compares two treatments: placebo, represented by a dashed line, and duloxetine, represented by a solid line. The x-axis shows time from 0 to 300 days, and the y-axis shows the proportion of patients with relapse from 0 to 1.*

FDA Label Image

Duloxetine-fig3.jpg (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph compares the effectiveness of different Duloxetine doses in improving patient pain levels.*

FDA Label Image

Duloxetine-fig4.jpg (Duloxetine Fig4)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The x-axis represents percent improvement in pain from baseline (0% to 100%), and the y-axis shows the percentage of patients improved (0% to 100%). Three lines show patient response differences between the dosing regimens and placebo over varying pain improvement thresholds.*

FDA Label Image

Duloxetine-fig5.jpg (Duloxetine Fig5)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating patient response rates across different pain improvement thresholds.*

FDA Label Image

Duloxetine-fig6.jpg (Duloxetine Fig6)

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. Each group's percentage of patients improved decreases as the percent improvement in pain increases, with placebo consistently showing the lowest improvement rates.*

FDA Label Image

Duloxetine-fig8.jpg (Duloxetine Fig8)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline, comparing Placebo and Duloxetine 60/120 mg once daily. The graph plots percent improvement on the x-axis and percentage of patients improved on the y-axis, illustrating treatment efficacy differences.*

FDA Label Image

Duloxetine-fig9.jpg (Duloxetine Fig9)

A line graph comparing the percentage of patients improved between placebo and duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Two lines illustrate that duloxetine generally results in higher patient improvement percentages across various pain improvement thresholds compared to placebo.*

FDA Label Image

Duloxetine-fig10.jpg (Duloxetine Fig10)

A line graph comparing the percentage of patients improved in pain from baseline between placebo and Duloxetine 60/120 mg once daily. The x-axis represents the percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved. The graph features two lines: one dashed for placebo and one solid for Duloxetine, illustrating patient response across various improvement thresholds.*

FDA Label Image

30 Capsules (Duloxetine 20)

Label for Duloxetine Delayed-release Capsules USP 20 mg by Alembic Pharmaceuticals Limited. The label includes dosing information, warning to check the integrity of the inner seal, manufacturer address in Gujarat, India, and a depiction of a green capsule marked with imprint '156'. The package contains 30 capsules and includes an NDC barcode and instructions for pharmacists to dispense accompanying medication guides.*

FDA Label Image

30 Capsules (Duloxetine 30)

Packaging label for Duloxetine Delayed-release Capsules USP, 30 mg strength. The label indicates 30 capsules per container and includes storage instructions to keep the capsules in a tightly closed container, out of reach of children, and store at 25°C. It is manufactured by Alembic Pharmaceuticals Limited. The label also notes the NDC 46708-279-30 and a prescription-only status.*

FDA Label Image

30 Capsules (Duloxetine 60)

Duloxetine Delayed-release Capsules USP, 60 mg, packaged in a 30-capsule container by Alembic Pharmaceuticals Limited. The label includes dosage equivalence, storage instructions (25°C with excursions 15°-30°C), a barcode, and warnings about seal integrity and child safety. It indicates prescription use and dispensing guidelines for pharmacists.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.